Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
#2PRI RANKED
Most Cited Paper
in Cancer-related Molecular Pathways
18 Months Post-Publication
Class of 2026
“Imlunestrant with or without Abemaciclib in Advanced Breast Cancer”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
imlunestrant · abemaciclib · selective estrogen-receptor degrader · ESR1 mutations · ER-positive breast cancer · HER2-negative breast cancer · advanced breast cancer · aromatase inhibitor · CDK4/6 inhibitor · progression-free survival · brain-penetrant oral agent · endocrine monotherapy · restricted mean survival time · imlunestrant-abemaciclib combination · EMBER-3 trial
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026. https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026. Accessed 2026-10-24. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459